Key points are not available for this paper at this time.
Objectives: Chylothorax can be congenital or acquired; however, there are no standardized treatment guidelines in neonates.In this study, we aimed to evaluate the experience of a tertiary neonatal intensive care unit. Materials and Methods:This single center retrospective study included neonates with chylothorax between 2012 and 2020.Demographic and clinical characteristics of patients were evaluated.Results: During the study period, 10 infants were diagnosed with chylothorax.The mean gestational age was 34.2±3.2weeks, and the mean birth weight was 2,655±685 g.Six (60%) of the cases had congenital chylothorax, and four (40%) had acquired chylothorax.Non-immune hydrops fetalis was identified in four (67%) of the six cases of congenital chylothorax.Intrauterine thoracentesis was performed in three cases.Acquired chylothorax cases (n=4) was occurred postoperatively.All infants were treated with octreotide.One patient underwent thoracic duct ligation.Eight (80%) of the patients were discharged with full recovery, and two (20%) died due to prematurity and heart failure after cardiac surgery.No shortterm recurrence was observed in any of the surviving cases. Conclusion:Chylothorax is a rare condition in neonates, and there is limited data about the management.This study will add knowledge of the use of octreotide treatment in neonatal chylothorax cases.
Köstekçi et al. (Tue,) studied this question.